title: Inhibitory effect of Abrus abrin-derived peptide fraction against Dalton's lymphoma ascites model.
abstract: Peptides derived from larger molecules that are important modulators in cancer regression are becoming leads for development of therapeutic drugs. It has been reported that Abrus abrin, isolated from the seeds of Abrus precatorius, showed in vitro and in vivo antitumor properties by the induction of apoptosis. The present study was designed to evaluate the in vivo therapeutic effectiveness of abrin-derived peptide (ABP) fraction in Dalton's lymphoma (DL) mice model. The lethal dose (LD(50)) of ABP was found to be 2.25 mg/kg body weight and further the acute toxicity was determined with sublethal doses in normal mice. The acute toxicity like body weight, peripheral blood cell count, lympho-hematological and biochemical parameters remained unaffected till 200 microg/kg body weight of ABP. The sublethal doses of ABP showed very significant growth inhibitory properties in vivo DL mice model. There were 24%, 70.8% and 89.7% reductions in DL cell survival in 25, 50 and 100 microg/kg body weight of ABP, respectively. Analysis of the growth inhibitory mechanism in DL cells revealed nuclear fragmentation, and condensation with the appearance of the sub-G(0)/G(1) peak is indicative of apoptosis. Further, the Western blotting showed that apoptosis was mediated by the reduction in the ratio of Bcl-2 and Bax protein expression, and activation of caspase-3 through the release of cytochrome c in DL cells. Kaplan-Meier survival analysis showed an effective antitumor response (104.6 increase in life span (ILS) %) with a dose of 100 microg/kg body weight.
authors.affiliation: Department of Biotechnology, Indian Institute of Technology, Kharagpur 721302, West Bengal, India.
authors.forename: Sujit K
authors.initials: SK
authors.lastname: Bhutia
authors.forename: Sanjaya K
authors.initials: SK
authors.lastname: Mallick
authors.forename: Swatilekha
authors.initials: S
authors.lastname: Maiti
authors.forename: Tapas K
authors.initials: TK
authors.lastname: Maiti
mesh_terms: D000036:Abrin / Q000627:therapeutic use* / Q000633:toxicity; D029912:Abrus; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D001201:Ascites / Q000188:drug therapy; D001772:Blood Cell Count; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006405:Hematology; D007928:Lethal Dose 50; D008223:Lymphoma / Q000188:drug therapy*; D051379:Mice; D010455:Peptides / Q000627:therapeutic use* / Q000633:toxicity; D008517:Phytotherapy; D010940:Plant Proteins / Q000627:therapeutic use* / Q000633:toxicity; D012639:Seeds; D013154:Spleen / Q000187:drug effects; D013534:Survival; D013950:Thymus Gland / Q000187:drug effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001786:Blood Glucose; D010455:Peptides; D010940:Plant Proteins; D000036:Abrin